Conv. Plasma
Nigella Sativa

All ivermectin studies
Meta analysis
study COVID-19 treatment researchIvermectinIvermectin (more..)
Melatonin Meta
Metformin Meta
Azvudine Meta
Bromhexine Meta Molnupiravir Meta
Budesonide Meta
Colchicine Meta
Conv. Plasma Meta Nigella Sativa Meta
Curcumin Meta Nitazoxanide Meta
Famotidine Meta Paxlovid Meta
Favipiravir Meta Quercetin Meta
Fluvoxamine Meta Remdesivir Meta
Hydroxychlor.. Meta Thermotherapy Meta
Ivermectin Meta

All Studies   Meta Analysis    Recent:   
0 0.5 1 1.5 2+ Mortality 92% Improvement Relative Risk Hospitalization 93% primary Ivermectin  Borody et al.  EARLY TREATMENT Is early treatment with ivermectin + zinc and doxycycline beneficial for COVID-19? Retrospective 600 patients in Australia (June - September 2021) Lower hospitalization with ivermectin + zinc and doxycycline (p<0.000001) Borody et al., TrialSite News, October 2021 Favors ivermectin Favors control

Combination Therapy For COVID-19 Based on Ivermectin in an Australian Population

Borody et al., TrialSite News
Oct 2021  
  Source   PDF   All   Meta
Ivermectin for COVID-19
4th treatment shown to reduce risk in August 2020
*, now known with p < 0.00000000001 from 103 studies, recognized in 22 countries.
No treatment is 100% effective. Protocols combine complementary and synergistic treatments. * >10% efficacy in meta analysis with ≥3 clinical studies.
4,100+ studies for 60+ treatments.
Retrospective 600 PCR+ outpatients in Australia treated with ivermectin, zinc, and doxycycline, showing significantly lower mortality and hospitalization with treatment. This trial uses a synthetic control group, and the preliminary report provides minimal details.
For discussion of the use of a synthetic control group, see Notably, advantages include less-biased recruitment (patients do not opt-out if they feel they need treatment and don't want to risk placebo), trials are cheaper, there is less delay in treatment, and trials can be run where it is not ethical to give patients placebo.
This is the 64th of 103 COVID-19 controlled studies for ivermectin, which collectively show efficacy with p<0.0000000001 (1 in 1 sextillion).
50 studies are RCTs, which show efficacy with p=0.00000014.
This study is excluded in the after exclusion results of meta analysis: preliminary report with minimal details.
risk of death, 92.3% lower, RR 0.08, p = 0.03, treatment 0 of 600 (0.0%), control 6 of 600 (1.0%), NNT 100, relative risk is not 0 because of continuity correction due to zero events (with reciprocal of the contrasting arm).
risk of hospitalization, 92.9% lower, RR 0.07, p < 0.001, treatment 5 of 600 (0.8%), control 70 of 600 (11.7%), NNT 9.2, primary outcome.
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
Borody et al., 19 Oct 2021, retrospective, Australia, preprint, 2 authors, study period 1 June, 2021 - 30 September, 2021, dosage 24mg days 1-10, this trial uses multiple treatments in the treatment arm (combined with zinc and doxycycline) - results of individual treatments may vary.
This PaperIvermectinAll
Abstract: COMBINATION THERAPY FOR COVID-19 BASED ON IVERMECTIN IN AN AUSTRALIAN POPULATION Authors: Thomas J. Borody1 MBBS, BSc(Med), MD, PhD, DSc, FRACP,FACP,FACG, AGAF Robert L. Clancy2 AM, MB BS PhD DSc FRACP FRCP(A) Affiliations: 1 Centre for Digestive Diseases, Five Dock, NSW, Australia, 2046 2 Faculty of Health and Medicine, University of Newcastle, NSW, Australia BACKGROUND The immediacy of “real-world” data in the pre-hospital treatment of Covid-19 using repurposed drugs has been the keystone to the development of effective therapy in a pandemic situation. The sense of a “common-message database” for the therapeutic use of ivermectin (IVM) collated by clinicians over a time frame of little more than 12 months, involving patients and research workers across geographic and social lines, is extraordinary. From over 20 countries there are 63 controlled studies accepted for meta-analysis, that have included 47,500 subjects with 625 authors. While this compelling database on the effectiveness of IVM would not be possible without “real-life” studies, at an individual level, these trials give additional value such as information on dosage and combination therapies. They also give confidence to local doctors and regulators as they seek optimal management strategies. Here, we report successful pre-hospital treatment of Covid-19 patients in Sydney and Melbourne, Australia, using an ivermectin-doxycycline-zinc combination with an important set of observations on symptom resolution and oximetry. THE STUDY Six hundred Australian residents with positive PCR symptomatic Covid-19 were treated with a combination of ivermectin (24 mg per day), doxycycline (100 mg bd), and zinc (50mg per day), for 10 days within 48 hrs of obtaining a positive PCR test for Covid-19. The treatment period was from June to September 2021. Seven percent (7%) were given additional vitamins and nutritional supplements. Only 7% identified adverse events from the therapy, mainly minor gut symptoms of nausea, diarrhoea and heartburn. No patient stopped therapy due to adverse drug events. A subgroup in hotel and home quarantine was available for a more detailed assessment of symptoms and oxygenation status. This cohort of 126 was assessed for 10 symptoms according to a visual analogue scale (ranging from “0” for no symptoms, to “10” for most severe symptoms). Descriptive statistics are summarised in Table 1. P-Values were calculated using Wilcoxon matched-pairs signed-rank t-tests. Chi Squared analysis was used to analyse rates of hospitalisation in the 600-patient cohort. THE OUTCOME A total of 600 patients with positive PCR tests were treated with the ten-day course of “Ivermectin Triple Therapy” (ITT), which was fully completed in over 90% of those treated. None discontinued therapy as a result of drug side effects. Two visited the hospital for less than 24 hours following a transient arrhythmia and then went home, while five were admitted to hospital (0.83%). There were no deaths. In an equivalent control group of 600, not treated with triple therapy, 70 were admitted to hospital (11.5%), with 6 deaths (1%). Chi-squared analysis of hospitalisation rate shows a significant decrease (P<0.001) in the presence of ivermectin triple therapy intervention. The control data was from contemporary infected subjects in Australia obtained from published Covid Tracking Data. The subgroup of 126 in quarantine had more detailed documentation. They had an average age of 42 (range: 17-94). The..
Please send us corrections, updates, or comments. c19early involves the extraction of 100,000+ datapoints from thousands of papers. Community updates help ensure high accuracy. Treatments and other interventions are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop